Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 18k
20 February 2019
Question for written answer E-000937-19
to the Commission
Rule 130
Philippe Juvin (PPE)

 Subject:  Consequences of Brexit in terms of health security
 Answer in writing 

In its resolution of 14 March 2018 on the framework of the future EU-UK relations, Parliament identifies as a priority in preparations for Brexit the need for ‘continued and safe access to medicines for veterinary and human use and medical devices for patients’.

Many pharmaceutical laboratories, given the importance of health security, have drawn up detailed contingency plans for ensuring continuity of supply of medicines, vaccines and other health products.

To date, the Commission’s communications (of 13 November and 19 December 2018) on preparations for the UK’s withdrawal from the EU have not included specific risk-prevention measures in respect of medicines and health. However, certain measures are not within the control of the pharmaceutical industry and have to be initiated by the Commission and Member States.

Does the Commission therefore envisage:
Accepting, unilaterally and temporarily, quality checks carried out at sites in the UK on products bound for the EU;
Disclosing and sharing the plans for preparedness at the Union’s borders, including with regard to IT systems?
Original language of question: FR 
Last updated: 5 March 2019Legal notice - Privacy policy